Similar articles

• Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

  Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB. Chung KY, et al. J Clin Oncol. 2005 Mar 20;23(9):1803-10. doi: 10.1200/JCO.2005.08.037. Epub 2005 Jan 27. J Clin Oncol. 2005. PMID: 15677699
• Cetuximab for colorectal cancer.

  Fraggetta F, Pelosi G. Fraggetta F, et al. N Engl J Med. 2008 Mar 13;358(11):1196; author reply 1196-7. N Engl J Med. 2008. PMID: 18340663 No abstract available.
• Is immunohistochemistry for epidermal growth factor receptor expression a poor predictor of response to epidermal growth factor receptor-targeted therapy?

  Younes M. Younes M. J Clin Oncol. 2005 Feb 1;23(4):923; author reply 923-4. doi: 10.1200/JCO.2005.05.111. J Clin Oncol. 2005. PMID: 15681544 No abstract available.
• Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer.

  Burtness B. Burtness B. Oncology (Williston Park). 2007 Jul;21(8):964-70; discussion 970, 974, 976-7. Oncology (Williston Park). 2007. PMID: 17715697 Review.
• Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab.

  You B, Chen EX. You B, et al. J Clin Pharmacol. 2012 Feb;52(2):128-55. doi: 10.1177/0091270010395940. J Clin Pharmacol. 2012. PMID: 21427284 Review.